Table 1.
Glycolysis inhibitors.
| Inhibitor | Target | virus |
|---|---|---|
| 2-DG | Phosphoglucose-isomerase | RV HIV HCMV |
| STO-609 Compound C AICAR |
CaMKK AMPK AMPK |
HCMV |
| Oxamate | Lactate-dehydrogenase | KSHV |
| VU0359595 | PLD-1 | HIV |
| Phloretin | GLUT1 | Zika virus (ZIKV) |
| Quercetin | GLUT1 | H5N1, hepatitis C virus (HCV), HBV, influenza A virus (IAV) H1N1, DENV-2, HSV-1, polio-virus type 1, Pf-3, RSV, ZIKV, EV71, HIV |
| STF31 | GLUT1 | – |
| WZB117 | GLUT1 | – |
| Fasentin | GLUT1 | – |
| Apigenin | GLUT1 | ASFV, EV71, HSV-1 and HSV-2, influenza, hepatitis C virus, virus, hand, foot, and mouth disease virus |
| Genistein | GLUT1 | B virus, HSV-1, Arenavirus, H1N1, H9N2, ASFV, human immunodeficiency type 1 virus |
| Oxime-based GLUT1 inhibitors | GLUT1 | – |
| Pyrrolidinone derived GLUT1 inhibitors | GLUT1 | – |
| DNA-damaging anticancer agents | GLUT3 | – |
| GSK-3 inhibitors | GLUT3 | – |
| Ritonavir | GLUT4 | HIV/AIDS |
| Silibinin | GLUT4 | hepatitis C virus, HSV-2, HBV, dengue virus, influenza virus, togaviruses (Chikungunya virus and Mayaro virus) |
| 3-(3-Pyridinyl)-1-(4-pyridinyl)-2-propen-1-one] 3PO | PFKFB3 | – |
| N4A | PFK2 | – |
| YZ9 | PFK2 | – |
| PGMI-004A | PGAM1 | – |
| MJE3 | PGAM1 | – |
| TT-232 | PKM2 | – |
| Shikonin/alkannin | PKM2 | HIV type 1, AdV3, H1N1 |
| FX11 | LDHA | – |
| 3-bromopyruvate (3BP) | hexokinase II | – |
| Dichloroacetate (DCA) | PDHK1 | – |
| Diarylsulfonamide (DASA-58) (DASA) | PDHK1 | – |
| Oxamic acid | LDH | – |
| NHI-1 | LDH A | – |
| PFK158 | PFKFB3 | – |
| 2-deoxyglucose (2-DG) | HK | HSV-1 |
| Sodium fluoride (NaF) | enolase | influenza virus A/PR8/34 (H0N1), poliomyelitis virus |
| Acidification of blood combined with the addition of NaF and EDTA | enolase | – |
| sodium fluoride–potassium oxalate (NaF–KOx) | enolase | – |
| arsenate compounds | glyceraldehyde-3-phosphate dehydrogenase | – |
| Sorbinil | aldose reductase inhibitor | – |
| Galloflavin | lactate dehydrogenase inhibitor | – |
| Lonidamine | mitochondrial HK2 | – |
| combination 3-BrOP and rapamycin | hexokinase II | – |
| combination MGCD265 and erlotinib | hexokinase II | Reactivation of hepatitis B virus after withdrawal of erlotinib |
| Dihydroartemisinin | pyruvate kinase M2 | – |
| AZD8055 | mTOR | – |
| Ethanol | hexokinase and alpha-glycerophosphate dehydrogenase | flu virus, the common cold virus, and HIV |
| Arenaemycin (pentalenolactone) | glyceraldehyde 3-phosphate dehydrogenase | – |
| Sorafenib | multikinase | Rift Valley Fever virus, HCV virus, Sindbis virus and chikungunya virus, EEEV, hepatitis B virus |
| 1-methyl-tryptophan | Indoleamine 2,3-dioxygenase | MHV-A59, HIV, HBV, HCV, herpes, CMV |
| Iodoacetate | glyceraldehyde-3-phosphate dehydrogenase | Sendai virus, progeny virus, potato virus X |
| Iodoacetamide | glyceraldehyde-3-phosphate dehydrogenase | bovine leukemia virus, tobacco mosaic virus, Rauscher leukemia virus, RS virus, poliovirus, psittacosis virus, Cricket paralysis virus |
| Ascorbic Acid | blocked the energy flux | * |
| LY294002 | PI3K | hepatitis C virus |
| Pt3glc and LY294002 | PI3K | – |
| mannoheptulose | glucokinase inhibitor | – |
| iodoacetic acid | glyceraldehyde-3-phosphate dehydrogenase | VSV, Sendai virus, HSV-1 |
| Malonate | succinate dehydrogenase | influenza and herpes viruses, measles virus |
| FTS | HIF1α expression | EMC-D virus |
| Lactate | PI3K | – |
| FK866 | NAMPT | – |
| 6-AN | G6PD | vaccinia virus |
| Oxythiamine | TKTL1 | – |
| pentalenolactone | glyceraldehyde-3-phosphate dehydrogenase | HSV-1, HSV-2, Vac-IHD, Vac-DIE, NDV, VSV, WEE |
| Compound C | AMP-activated protein kinase | HCMV |
| FUT-175 | complement inhibitor | – |
| Luteolin | HEK2 | dengue virus, influenza A virus, HIV-1, Hepatitis B virus, pseudorabies virus, Epstein-Barr virus, Japanese encephalitis virus, Chikungunya virus |
| Quinoline 3-sulfonamides | LDHA | – |